Privi Speciality Chemicals (PRIVISCL) Q3 25/26 earnings summary

Executive summary

• Delivered robust performance with 24% YoY revenue growth in Q3 and nine months, driven by a diversified product mix, operational excellence, and innovation focus.

• Strategic focus on becoming a world-class aroma chemical company through disciplined execution, sustainability, and capacity expansion.

• Amalgamation of subsidiaries underway to unlock synergies and enhance operational efficiency.

• Unaudited consolidated and standalone financial results for the quarter and nine months ended December 31, 2025, were reviewed and approved on February 9, 2026.

• Statutory auditors expressed an unmodified review conclusion for both consolidated and standalone results.

Financial highlights

• Q3 FY26 consolidated revenue was INR 611.15 crore (up 24% YoY); nine-month revenue reached INR 1,857 crore (up 24% YoY).

• Q3 EBITDA grew 37% YoY to INR 158 crore, with a margin of 25.83%; nine-month EBITDA reached INR 481 crore, up 47% YoY.

• Adjusted Q3 PAT was INR 82 crore, up from INR 44 crore YoY; nine-month adjusted PAT was INR 232 crore, up 84% YoY.

• Basic and diluted EPS (consolidated) for Q3 FY26 was INR 19.97, up from INR 11.38 in Q3 FY25.

• One-time expense of INR 3.9 crore due to new labor legislation in Nov 2025.

Outlook and guidance

• Targeting INR 5,000 crore revenue and INR 1,000 crore EBITDA within 3-4 years, with EBITDA margins expected to remain above 20%.

• Capacity expansion to 54,000 MT by April 2026, with further specialty product capacity to be added in subsequent phases.

• Volume growth expected at 7% for the coming year, potentially reaching 11-15% depending on project ramp-up.

• Continued investments in green chemistry, biotechnology, and digital transformation.

• The company continues to monitor the impact of new labour codes and will recognize adjustments as needed.